Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
Year: 2014
Type: review
Study designs: Systematic Review, Meta-Analysis
Source: The Lancet Oncology
Institutions: Massachusetts General Hospital, GlaxoSmithKline (Germany), Harvard University, Dana-Farber Cancer Institute, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University Hospital Zurich, Institut Gustave Roussy, Christian-Albrechts-Universität zu Kiel, University Hospital Schleswig-Holstein, The University of Sydney, Westmead Hospital, Melanoma Institute Australia, UPMC Hillman Cancer Center, University of Manchester, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Peter MacCallum Cancer Centre, Beverly Hills Cancer Center, University of Nottingham, Inserm, Essen University Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
Award: G323827386
OpenAlex ID: W2116046724
